Lipotoxicity in NASH
- Prof. Kenneth Cusi
- 1 min
That’s a very important concept because lipotoxicity is a driver of steatosis and triglyceride accumulation that later on are going to lead to some toxic metabolites that are going to promote inflammation and presumably fibrosis, so insulin resistance and adipose tissue is extremely important as is the target of treatment because when the adipose tissue is insulin resistant, it will release fatty acids into a circulation and those fatty acids have to go to other tissues to be metabolized.Now these other tissues like the liver or muscle are not used to this high influx of fatty acids. So it causes dysfunction of these cells and in the case of the parasitic inflammatory response at least in simplistic terms.
For clinicians:
So treatments that will reverse this process like life intervention or at PPAR (Peroxisome proliferator-activated receptor) gamma are going to have a huge impact on steatosis and many times on inflammation or fibrosis.
Would you like to read more?
Prof. Kenneth Cusi
Prof. Kenneth Cusi, a leading expert in Endocrinology, currently serves as the Chief of the Division of Endocrinology at the University of Florida. Renowned for his groundbreaking work on the correlation between NAFLD and T2DM, Prof. Cusi has published over 150 articles in leading medical journals and received numerous accolades for his contributions to medicine.
Delving into the Latest Advancements in MASLD Treatment: Key Insights from Prof. Wong’s presentations at AASLD
International NASH Day 2023: Empowering Healthcare Professionals
Nordic NASH Symposium
The role of circadian clocks in the pathogenesis of NAFLD
Hepatocellular carcinoma surveillance in NAFLD patients
MAFLD and inflammatory bowel disease: a prospective cohort study
Coffee achieves its beneficial effects through modulation of insulin resistance in a NAFLD mouse model
B cells aggravate NASH: an innate and adaptive signalling
NAFLD: from drivers to targets
NASH: an Overview Through 200 Years of Clinical Research
Immune cell-mediated features of NASH
Steatohepatitis: hypothesis for a pathomechanism
SUBSCRIBE & FOLLOW US
Subscribe Our Newsletter To Get the Lastest Updates
Related Videos
Clinical Chemistry In NAFLD Part 3 – Biomarkers and Hepatic Fibrosis
- Dr Guillaume Grzych
- 10 mins
Clinical Chemistry in NAFLD Part 2 – Biomarkers, Hepatic Steatosis and NASH
- Dr Guillaume Grzych
- 11 mins
Key Messages from 2 Recent Studies on NAFLD Severity in People with Type 2 Diabetes
- Prof. Laurent Castera
- 13 mins